Alkem Laboratories Ltd (ALKEM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Alkem Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
With reference to your email regarding the captioned corporate announcement submitted by the Company on 03rd November, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure ....
Change in Management · 05 Nov 2026, 9:55 pm
Alkem Laboratories Appoints Dr. Amrut Naik as Chief Executive Officer Alkem Laboratories appointed Dr. Amrut Naik as Chief Executive Officer and Key Managerial Personnel, effective 11th Nov'26, following the Board of Directors' approval on 3rd Nov'26. Dr. Naik brings over 26 years of global pharmaceutical leadership experience across Branded Formulations, Generics, APIs, Biologics, Vaccines, and Specialty segments. He holds a Ph.D. in Pharmacology alongside master's and bachelor's degrees in Pharmaceutical Science. His tenure is tied to the duration of his employment contract, with no disclosed inter-director relationships.
Please find attached herewith intimation for Analyst / Investor Meet.
Intimation · 12 Nov 2026, 4:30 pm
Alkem Laboratories Schedules Q2FY27 and H1FY27 Earnings Conference Call Alkem Laboratories Ltd. will host an earnings conference call for investors and analysts on 12th Nov'26 from 4:30 PM to 5:30 PM IST to discuss its Q2FY27 and H1FY27 financial results. The call follows the official earnings release scheduled for the same day and will be hosted by Motilal Oswal Securities Ltd. Key management representatives attending include Managing Director Sandeep Singh, CEO Dr. Amrut Naik, and Deputy CFO Dishant Hitesh Doshi.
Please find attached herewith intimation for Analyst / Investor Meet.
Intimation · 12 Nov 2026, 4:30 pm
Alkem Laboratories Schedules Q2 and H1FY27 Earnings Conference Call Alkem Laboratories Ltd. will host an earnings conference call for investors and analysts on 12th Nov'26 from 4:30 pm to 5:30 pm IST to discuss its financial results for Q2FY27 and H1FY27, following their announcement earlier that day. Hosted by Motilal Oswal Securities Ltd., the management will be represented by Managing Director Sandeep Singh, CEO Dr. Amrut Naik, and Deputy CFO Dishant Hitesh Doshi.
ALKEM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 12 Nov 2026, 5:30 am
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve the Standalone and Consolidated ....
Intimation · 12 Nov 2026, 5:30 am
Alkem Laboratories Board to Consider Q2 and H1 Results on 12th Nov'26 Alkem Laboratories Limited has informed the exchanges that a meeting of its Board of Directors is scheduled for 12th Nov'26. The board will, inter alia, consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26.
to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026.
Intimation · 12 Nov 2026, 5:30 am
We wish to inform you that M/s. Alkem Laboratories Limited has appointed Dr. Amrut Naik as the Chief Executive Officer (CEO) and Key Managerial Personnel of the Company with effect from ....
Change in Management · 03 Nov 2026, 7:04 pm
Alkem Laboratories Appoints Dr. Amrut Naik as Chief Executive Officer Alkem Laboratories Limited has appointed Dr. Amrut Naik as Chief Executive Officer and Key Managerial Personnel, effective 11th Nov'26, following the Nomination and Remuneration Committee's recommendation on 3rd Nov'26. Dr. Naik brings over 26 years of global pharmaceutical experience across branded formulations, generics, APIs, biologics, vaccines, and specialty portfolios. He holds a Ph.D. in Tech (Pharmacology) along with Master's and Bachelor's degrees in Pharmaceutical Science.
Update On US FDA Inspection At Company's API manufacturing facility located at Mandva.
Press Release · 30 Oct 2026, 8:52 pm
Alkem Laboratories Concludes US FDA Inspection at Mandva API Facility with Zero Form 483 Observations Alkem Laboratories announced that the US FDA successfully concluded an inspection at its API manufacturing facility located in Mandva. The regulatory audit was conducted from 26th Oct'26 to 30th Oct'26 and concluded with zero Form 483 observations, confirming strong compliance standards and mitigating regulatory overhang for the site.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Part A of Schedule III thereto, we wish to inform you that ....
Others (Uncategorized) · 22 Oct 2026, 3:17 am
Alkem Laboratories Initiates Forensic Audit Over Suspected Fund Misappropriation Alkem Laboratories announced on 21st Oct'26 that its Audit Committee approved initiating a forensic audit following an alleged misappropriation of funds by a former employee. Grant Thornton Bharat LLP has been appointed to perform a preliminary electronically stored information (ESI) review and gather market intelligence regarding procurement activities handled by the former employee. The audit aims to independently investigate suspected transactional irregularities, determine the root cause, establish full circumstances, and recommend corrective measures.
Please find attached herewith intimation for appointment of Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as Senior Management Personnels of the Company.
Change in Management · 12 Oct 2026, 9:12 pm
Alkem Laboratories Appoints Laxmikant Tiwari and Nilesh Vartak to Senior Management Alkem Laboratories Limited has appointed Mr. Laxmikant Tiwari and Mr. Nilesh Vartak to senior management positions, effective 12th Oct'26. Mr. Tiwari brings over 27 years of experience in pharmaceutical operations and holds a Bachelor's in Pharmacy alongside an MBA in Operations Management. Mr. Vartak possesses over 24 years of supply chain leadership experience across the pharmaceutical, healthcare, and consumer goods sectors, holding a Marine Engineering degree and an MBA in Finance. Both appointments are permanent for the duration of their employment.
Please find attached herewith intimation for change in Key Managerial Personnel - Resignation of Chief Financial Officer
Change in Management · 24 Sept 2026, 6:13 pm
Alkem Laboratories Announces Resignation of CFO Nitin Agrawal Effective 30th Sep'26 Alkem Laboratories has disclosed the resignation of its Chief Financial Officer and Key Managerial Personnel, Nitin Agrawal, tendered on 30th Jul'26 to pursue external professional opportunities. Agrawal will officially step down from his senior management role on 30th Sep'26. During his tenure, Agrawal oversaw key strategic initiatives, including building the MedTech vertical, executing acquisitions such as Adroit and Bombay Ortho, forming the Saudi joint venture, liquidating idle assets, and recently driving the acquisition of Occlutech. The company will ensure a transition of responsibilities prior to his departure.
Please find attached herewith intimation of Schedule of Analyst / Institutional Investor Meeting.
Intimation · 23 Sept 2026, 7:55 pm
Alkem Laboratories Schedules Investor Meeting with HDFC Mutual Fund Alkem Laboratories Limited has scheduled an in-person, one-on-one institutional investor meeting with HDFC Mutual Fund on 7th Oct'26 in Mumbai. The interaction is subject to change based on exigencies from either party, pursuant to SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Please find attached herewith intimation for issue of corporate guarantee by the Company.
Others (Uncategorized) · 21 Sept 2026, 11:13 pm
Alkem Laboratories Issues €54.45 Million Corporate Guarantee for Swiss Step-Down Subsidiary On 21st Sep'26, Alkem Laboratories issued an arm’s length corporate guarantee of €54.45 million to HSBC UK Bank plc. The guarantee secures a €49.5 million term loan availed by its Switzerland-based step-down subsidiary, Occlutech Holding AG. The promoter and promoter group have no interest in the transaction. The guarantee represents a contingent liability for Alkem Laboratories, executable solely in the event of default by Occlutech.
Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial - onset seizures in adult patients.
Press Release · 16 Sept 2026, 5:19 pm
Alkem Laboratories Launches NeuCeno for Partial-Onset Seizure Treatment in India On 16th Sep'26, Alkem Laboratories announced the launch of NeuCeno (cenobamate) in India for treating partial-onset seizures in adults, marking the molecule's first entry into the domestic market. NeuCeno is a once-daily oral anti-seizure medication available in dosages ranging from 12.5 mg to 200 mg. Clinical data demonstrated up to a 78% reduction in seizure frequency, with up to 30% of patients achieving seizure freedom during the maintenance phase, targeting an estimated 9.4 million epilepsy patients across India.
Please find attached herewith intimation for appointment of Dr. Shubhadeep Sinha as Senior Management Personnel of the Company.
Change in Management · 16 Sept 2026, 2:45 am
Alkem Laboratories Appoints Dr. Shubhadeep Sinha to Senior Management Alkem Laboratories Limited has appointed Dr. Shubhadeep Sinha to a Senior Management position, effective 15th Sep'26, as per its regulatory disclosure under SEBI LODR Regulations. Dr. Sinha brings over 25 years of experience spanning Clinical Development, Medical Affairs, Pharmacovigilance, Regulatory Affairs, and Healthcare Management. The appointment is contractual for the duration of his employment with the company.
Alkem Laboratories Limited launches Renocia ExoTM, India''s first patented Ginsenoside Exosome - based hair growth serum
Press Release · 08 Sept 2026, 8:39 pm
Alkem Laboratories Launches Renocia Exo Hair Growth Serum in India Alkem Laboratories announced on 8th Sep'26 the launch of Renocia Exo™, India’s first patented Ginsenoside Exosome-based hair growth serum, targeting the fast-growing hair loss market. The product integrates Ginsenoside phyto-exosomes, biomimetic peptides, copper peptides, and stem cell-supportive actives into a single daily therapy to support follicular vitality and scalp health. The launch strengthens Alkem's expanding dermatology and chronic therapy portfolio, complementing its dominant domestic positions in anti-infectives, gastrointestinal, and pain management segments.
Please find attached herewith Scrutinizer Report for 52nd Annual General Meeting of the Company.
Annual General Meeting · 28 Aug 2026, 12:11 am
Please find attached herewith Outcome of the 52nd Annual General Meeting of the Company and disclosure of voting results thereat.
Annual General Meeting · 28 Aug 2026, 12:05 am
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund
Acquisition/ Disposal of Shares · 26 Aug 2026, 10:53 pm
HDFC Mutual Fund Crosses 5% Stake in Alkem Laboratories HDFC Mutual Fund's aggregate holding in Alkem Laboratories crossed the 5% threshold, reaching 5.017% of paid-up equity share capital as of 24 Aug'26. The fund acquired 25,019 shares (0.021% stake) via an open market transaction on this date. Before the acquisition, HDFC MF held 59,73,409 shares (4.996%). Post-acquisition, its total holding stands at 59,98,428 shares. The company's total paid-up capital is Rs. 23.91 crore, comprising 11.96 crore equity shares of Rs. 2 each.
Please find attached herewith Q1 FY27- Earnings Call Transcript.
Transcript · 20 Aug 2026, 11:31 pm
Please find attached herewith Q1 FY27- Earnings Call Transcript.
Transcript · 20 Aug 2026, 11:30 pm
Please find attached herewith Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer''s Report on e-voting.
Court Convened Meeting · 18 Aug 2026, 12:32 am
Alkem Shareholders Approve Amalgamation with Adroit Biomed Alkem Laboratories' shareholders approved the scheme of amalgamation with Adroit Biomed Limited at the NCLT-convened meeting on 17th Aug'26. The special resolution received overwhelming support, with 99.9999% of total votes cast in favor. The voting, conducted via remote e-voting and e-voting at the meeting, saw a total participation representing 99.98 million shares, or 83.62% of the total share capital. The promoter group voted entirely in favor of the resolution. The amalgamation is now subject to final NCLT approval.
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the '' Q1FY27 Earnings Conference Call'' is available ....
Audio / Video · 15 Aug 2026, 12:44 am
Alkem Labs Makes Q1FY27 Earnings Call Recording Available Alkem Laboratories has released the audio recording of its Q1FY27 earnings conference call, as per a regulatory filing on 14th Aug'26. The recording is accessible on the company's investor relations website. This provides stakeholders with direct access to management's discussion and analysis of the quarterly performance and outlook.
Pl find enclosed press release and analyst presentation on Q1FY27 earnings and business updates of the Company
Investor Presentation · 14 Aug 2026, 7:27 pm
Alkem Q1FY27: Revenue Up, Profit Down on Higher R&D and Lower Margins Alkem Labs reported Q1FY27 revenue of ₹37,402 Mn, up 10.9% YoY, driven by strong international sales (+16.0%). EBITDA grew 3.7% YoY to ₹7,661 Mn, but the margin compressed to 20.5% from 21.9% a year ago. Net Profit saw a significant decline of 21.7% YoY to ₹5,200 Mn, with PAT margin at 13.9% vs. 19.7%. This was impacted by a 27.7% YoY increase in R&D expenses to ₹1,502 Mn (4.0% of sales). A key regulatory update was an OAI for its Daman plant.
Pl find attached herewith intimation under Reg 30
Others (Uncategorized) · 14 Aug 2026, 7:25 pm
Alkem Labs to Invest INR 75 Crore in Baddi Facility Expansion Alkem Laboratories announced on 14 Aug'26 that its Board of Directors has approved an investment of up to INR 75 crores for expansion. The capital will be used to set up a new block within the company's existing manufacturing facility located at Baddi, Himachal Pradesh. This move signals a capacity expansion at a key production site.